about
Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly peopleCerebrospinal fluid analysis detects cerebral amyloid-β accumulation earlier than positron emission tomographyA Genetic Variant of the Sortilin 1 Gene is Associated with Reduced Risk of Alzheimer's DiseaseSoluble TNF receptors are associated with Aβ metabolism and conversion to dementia in subjects with mild cognitive impairmentSystematic development of small molecules to inhibit specific microscopic steps of Aβ42 aggregation in Alzheimer's diseaseComparison of brief cognitive tests and CSF biomarkers in predicting Alzheimer's disease in mild cognitive impairment: six-year follow-up studyAβ40 oligomers identified as a potential biomarker for the diagnosis of Alzheimer's diseaseClinical validity of cerebrospinal fluid Aβ42, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework.Extrapolation-Based References Improve Motion and Eddy-Current Correction of High B-Value DWI Data: Application in Parkinson's Disease Dementia.Evaluating amyloid-β oligomers in cerebrospinal fluid as a biomarker for Alzheimer's diseaseOverexpression of heat shock protein 70 in R6/2 Huntington's disease mice has only modest effects on disease progression.Lack of neuroprotection by heat shock protein 70 overexpression in a mouse model of global cerebral ischemia.Novel panel of cerebrospinal fluid biomarkers for the prediction of progression to Alzheimer dementia in patients with mild cognitive impairment.Distinct cerebrospinal fluid amyloid beta peptide signatures in sporadic and PSEN1 A431E-associated familial Alzheimer's disease.Time to Amyloid Positivity and Preclinical Changes in Brain Metabolism, Atrophy, and Cognition: Evidence for Emerging Amyloid Pathology in Alzheimer's DiseaseNG2 cells, a new trail for Alzheimer's disease mechanisms?Recommendations for cerebrospinal fluid collection for the analysis by ELISA of neurogranin trunc P75, α-synuclein, and total tau in combination with Aβ(1-42)/Aβ(1-40)Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson's disease with dementia and dementia with Lewy bodies compared to Alzheimer's diseaseImproving the survival of grafted dopaminergic neurons: a review over current approaches.Alterations of matrix metalloproteinases in the healthy elderly with increased risk of prodromal Alzheimer's disease.Identification of SPARC-like 1 protein as part of a biomarker panel for Alzheimer's disease in cerebrospinal fluid.Improving the survival of grafted embryonic dopamine neurons in rodent models of Parkinson's disease.Efficacy of memantine in PDD and DLB: an extension study including washout and open-label treatment.Evaluation of a previously suggested plasma biomarker panel to identify Alzheimer's disease.A Quick Test of cognitive speed is sensitive in detecting early treatment response in Alzheimer's disease.Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid β-amyloid 42: a cross-validation study against amyloid positron emission tomography.Non-motor symptoms in patients with Parkinson's disease - correlations with inflammatory cytokines in serumDetailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer diseaseNo diagnostic value of plasma clusterin in Alzheimer's disease.Low CSF levels of both α-synuclein and the α-synuclein cleaving enzyme neurosin in patients with synucleinopathySNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer's disease.Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers.Proinflammatory cytokines are elevated in serum of patients with multiple system atrophyAssessment of global and regional diffusion changes along white matter tracts in parkinsonian disorders by MR tractography.Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment.Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease.Cerebrospinal fluid inflammatory markers in Parkinson's disease--associations with depression, fatigue, and cognitive impairment.Practical suggestions on how to differentiate dementia with Lewy bodies from Alzheimer's disease with common cognitive tests.Prediction of falls and/or near falls in people with mild Parkinson's diseaseCerebrospinal fluid (CSF) 25-hydroxyvitamin D concentration and CSF acetylcholinesterase activity are reduced in patients with Alzheimer's disease.
P50
Q22253051-2B0808E4-008D-4424-A23F-6F767BD43543Q28273817-07EDD1B6-D67B-4B26-B68A-6BD62A2C04E8Q28276977-F2432DAA-D7D7-4AF0-82C0-CE4147A4252FQ28303469-EEE81689-E31D-4E39-8D9D-C817B6244660Q28468287-E0B4F9DC-9A76-4B67-B52F-2931DE1B0F60Q28728080-DBC11799-C72E-40E2-B6D1-E754A2B396B2Q28743838-14E3CEB9-3383-4702-BF7B-036BFEAB474EQ30235198-8251952D-6A58-48CA-841D-7BDB2E671D6FQ31015635-2097FA6D-ABEF-4826-90D6-A56EFDD3F138Q31120924-1D9A1FB3-C9DE-460D-8331-9E443335BA60Q31139684-12099ECF-C7F6-4730-8BA6-027E576C7AC2Q33194237-580F7367-BBCA-4687-93A8-29EC52C39947Q33278028-36028A63-724B-4844-9D72-B4F550434626Q33638748-52DD9224-C28C-4CDA-A16A-7B45BFC94C42Q33695122-311CD362-A22F-470B-B8EC-EC4CEFF4B12EQ33715573-9FFDA959-614B-4E82-BE36-119E1BD1494CQ33771776-A30C4ADB-E9B6-46EA-98DC-8C0A7CB09CF9Q33822641-0390D804-785E-4F14-B29D-59F2F4110D59Q33918866-233CDD3A-3819-45F2-A50E-6E01E3E98AC8Q34058311-80E93B7E-3D72-4D20-B2A3-33955A6EB19CQ34063961-44EDAF7D-CDD9-46E1-B938-50FEA9774472Q34120728-146E96C6-BFC2-4453-8F82-6E62E62094C3Q34128361-94AD817F-52A5-45B5-9C0A-CBAC29A511E1Q34141675-9188C684-9316-4B73-BD4E-5605381DDDB5Q34318028-AAA35A8A-09FF-4543-AAB6-890B76F65193Q34435040-75ADD0E8-22B5-442B-9C1D-71A7002568AAQ34452085-9C2BBDC7-9357-42EE-AC18-4CA087BFAF1EQ34493453-C7258BAA-E36D-4646-B08A-06E7073756A7Q34500043-913155B5-BA6C-4DD5-A000-19A9A87141A7Q34544824-151E8D09-3C92-4D4D-8268-78D5D89EE98AQ34620335-D0E0CBF8-1779-4BE0-A5A5-0ED1F751089CQ34682521-C2B383FB-7232-40F5-92F9-50E67738772CQ34693025-88651D9F-23CA-4557-B8C2-1CCA8353701CQ34778809-469DF731-7AFF-469A-8C5D-E70BF2D00E45Q34779254-1D95C01B-B8D2-4CC4-B193-A51770A07B82Q34807142-8A54C5B7-CFF1-4A46-8D0E-7CF16FD25E21Q34890677-CF39A032-FB93-45DE-92D8-350226B1B208Q34974315-698DC364-C3CB-4428-874F-882E5054D4D2Q35031923-8574B6CA-93DB-4710-B052-67B9C8F125FFQ35060833-7112F77A-BA1D-4A6F-A76C-FEB3816F8990
P50
description
Professor at Clinical Memory Research
@en
Zweeds onderzoeker
@nl
hulumtues
@sq
professor
@sv
հետազոտող
@hy
name
Oskar Hansson
@ast
Oskar Hansson
@en
Oskar Hansson
@es
Oskar Hansson
@fr
Oskar Hansson
@nl
Oskar Hansson
@sl
Oskar Hansson
@sv
type
label
Oskar Hansson
@ast
Oskar Hansson
@en
Oskar Hansson
@es
Oskar Hansson
@fr
Oskar Hansson
@nl
Oskar Hansson
@sl
Oskar Hansson
@sv
altLabel
O Hansson
@en
prefLabel
Oskar Hansson
@ast
Oskar Hansson
@en
Oskar Hansson
@es
Oskar Hansson
@fr
Oskar Hansson
@nl
Oskar Hansson
@sl
Oskar Hansson
@sv
P1053
A-7134-2013
P106
P1153
7006190615
P1960
61zbXSIAAAAJ
P21
P27
P31
P3829
P4012
P496
0000-0001-8467-7286
P6634
oskar-hansson-51187a104